Trial Profile
Twin SUBLIVAC Grasses Clinical Efficacy Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic asthma; Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors HAL Allergy
- 15 Sep 2009 Actual end date (1 Oct 2007) added as reported by ClinicalTrials.gov.
- 15 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Mar 2008 The expected completion date for this trial is now 1 Nov 2009, reported by ClinicalTrials.gov. Planned patient number also updated.